BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

pharmafile | April 5, 2019 | News story | Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo 

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to patients in England via the Cancer Drugs Fund (CDF) for the first-line treatment of untreated renal cell carcinoma (RCC), the most common form of kidney cancer.

The drug’s immediate availability through this new pathway provides RCC with another treatment option, which is particularly meaningful as current NHS standard of treatment such as pazopanib, sunitinib, tivozanib or cabozantinib are associated with side-effects including hand and foot syndrome and fatigue.

The decision was based on Phase 3 data derived from 1,096 patients. The trial was stopped early once it was established that BMS’ drug combo proved itself superior to sunitinib in extending overall survival.

In the UK, RCC is the seventh most common form of cancer, with rates having risen 47% in approximately the last ten years. There were more than 12,500 diagnoses of the disease in 2015, which kills around 4,500 people in the UK every year, particularly as between 25% and 31% of UK patients were diagnosed at an already advanced stage, with only 5% surviving stage 4 forms for five years or more.

“Today’s decision is of importance to advanced kidney cancer patients, who may now have access to more treatment options,” said Rose Woodward, Co-founder of the Kidney Cancer Support Network. “Kidney cancer is a devastating disease and at the most advanced stage prognosis is poor. Having access to this combination therapy on the NHS is therefore an important new addition and a vital step in our fight to extend survival.”

Lynelle Hoch, General Manager at BMS UK & Ireland, commented: “We are delighted that NICE has recognised the combination of nivolumab plus ipilimumab as an important treatment option for many patients with advanced RCC. Importantly, the decision may allow intermediate- and poor risk patients in England to receive immunotherapy as a first-line option for the first time.”

Matt Fellows

Related Content

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

Latest content